Can eye injections stop wet AMD before it starts?
NCT ID NCT02462889
First seen Nov 15, 2025 · Last updated Jun 21, 2026 · Updated 28 times
Summary
This study tested whether injections of aflibercept (Eylea) into the eye could prevent the development of wet age-related macular degeneration (AMD) in people at high risk. 128 participants with early signs of AMD in one eye and wet AMD in the other eye received either Eylea or a sham injection. The main goal was to see if Eylea could reduce the chance of the high-risk eye converting to wet AMD over two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
NJ Retina
Edison, New Jersey, 08817, United States
-
Ophthalmic Consultants of Boston
Boston, Massachusetts, 02114, United States
-
Retina Consultants of Houston
Houston, Texas, 77030, United States
-
Retina-Vitreous Associates Medical Group
Beverly Hills, California, 90211, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aflibercept (Eylea)
What this could lead to
If successful, this could point toward a preventive treatment for wet AMD in people at high risk, potentially saving vision.
What could go wrong
This is a small, early-phase trial with only 128 participants. The results may not apply to everyone, and the treatment involves regular eye injections with risks like infection or inflammation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.